Pharmaceuticals (Jun 2021)

Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management

  • Francesca Spada,
  • Roberta E. Rossi,
  • Elda Kara,
  • Alice Laffi,
  • Sara Massironi,
  • Manila Rubino,
  • Franco Grimaldi,
  • Sherrie Bhoori,
  • Nicola Fazio

DOI
https://doi.org/10.3390/ph14060539
Journal volume & issue
Vol. 14, no. 6
p. 539

Abstract

Read online

The carcinoid syndrome (CS) and hyperinsulinemic hypoglycemia (HH) represent two of the most common clinical syndromes associated with neuroendocrine neoplasms (NENs). The former is mainly related to the serotonin secretion by a small bowel NEN, whereas the latter depends on an insulin hypersecretion by a pancreatic insulinoma. Both syndromes/conditions can affect prognosis and quality of life of patients with NENs. They are often diagnosed late when patients become strongly symptomatic. Therefore, their early detection and management are a critical step in the clinical management of NEN patients. A dedicated and experienced multidisciplinary team with appropriate therapeutic strategies is needed and should be encouraged to optimize clinical outcomes. This review aims to critically analyze clinical features, evidence and treatment options of CS and HH and therefore to improve their management.

Keywords